CUE-501 / Cue Biopharma, Boehringer Ingelheim - LARVOL DELTA

Development of a novel fusion protein platform for T-cell-mediated depletion to reset the immune system in autoimmune diseases (AAAAI 2026) - "In vivo, the murine surrogate CUE-501 molecule demonstrated selective engagement of murine B cells. Conclusions With potent cytotoxicity and significantly less proinflammatory cytokine production in vitro, the CUE-500 Series represents a promising potential alternative to CAR-T and bispecific T-cell engagers for the depletion of pathological cells in autoimmune diseases."

Food Hypersensitivity • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • CD8 • HLA-A • IFNG • TNFA

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases (GlobeNewswire) - "Boehringer Ingelheim and Cue Biopharma...announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases....Under the terms of the agreement, Cue Biopharma’s technology will be leveraged to further research and advance the development of the candidate molecule. The terms of the multi-year collaboration also include the ability of the parties to expand research and potential development into various B cell targeting bispecifics encompassing autoimmune diseases."

Licensing / partnership • Immunology • Inflammation